Last reviewed · How we verify

Gabapentin, Etoricoxib, Sugar pill

Meir Medical Center · FDA-approved active Small molecule

This is a combination product containing gabapentin (a gabapentinoid that modulates calcium channels to reduce neuronal excitability), etoricoxib (a selective COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain), and a placebo control.

This is a combination product containing gabapentin (a gabapentinoid that modulates calcium channels to reduce neuronal excitability), etoricoxib (a selective COX-2 inhibitor that reduces prostaglandin-mediated inflammation and pain), and a placebo control. Used for Neuropathic pain (gabapentin component), Inflammatory pain and osteoarthritis (etoricoxib component).

At a glance

Generic nameGabapentin, Etoricoxib, Sugar pill
SponsorMeir Medical Center
Drug classCombination analgesic (gabapentinoid + selective COX-2 inhibitor + placebo)
TargetAlpha-2-delta calcium channel subunit (gabapentin); COX-2 (etoricoxib)
ModalitySmall molecule
Therapeutic areaPain Management / Neurology
PhaseFDA-approved

Mechanism of action

Gabapentin binds to the alpha-2-delta subunit of voltage-gated calcium channels in the central nervous system, reducing the release of excitatory neurotransmitters and thereby decreasing neuropathic pain signaling. Etoricoxib selectively inhibits cyclooxygenase-2 (COX-2), reducing the production of pro-inflammatory prostaglandins and providing analgesic and anti-inflammatory effects. The sugar pill serves as a placebo control component.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: